Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

IHOP > CINV > Flashcards

CINV Flashcards

1
Q

LIST risk factors for CINV.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Define acute CINV.

A

Within 24 hours (peak 4-6 hours)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Define delayed CINV.

A

After 1-5 days (peak 2-3 days)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Define anticipatory CINV.

A

Before therapy (sights, smells, sounds); risk factors (treatment > 6 months, h/o anxiety/depression, h/o poor anti-emetic control)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe the QOL impact of CINV.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe the pathophysiology of CINV.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the role of 5-HT and NK-1 in acute CINV.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the role of 5-HT and NK-1 in delayed CINV.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Describe the MOA of 5-HT3 antagonists.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe the MOA of corticosteroids.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe the MOA of NK-1 antagonists.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe the MOA of olanzapine.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Describe the MOA of benzodiazepines.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe the MOA of phenothiazines.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe the MOA of butyrophenones.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the MOA of cannabinoids.

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

LIST common side effects & potential drug related problems with 5-HT3 antagonists.

A
18
Q

LIST common side effects & potential drug related problems with corticosteroids.

A
19
Q

LIST common side effects & potential drug related problems with NK-1 antagonists.

A
20
Q

LIST common side effects & potential drug related problems with olanzapine.

A
21
Q

LIST common side effects & potential drug related problems with benzodiazepines.

A
22
Q

LIST common side effects & potential drug related problems with phenothiazines.

A
23
Q

LIST common side effects & potential drug related problems with butyrophenones.

A
24
Q

LIST common side effects & potential drug related problems with cannabinoids.

A
25
Q

Identify the common doses and brand/generic name of ondansetron.

A
26
Q

Identify the common doses and brand/generic name of palonosetron.

A
27
Q

Identify the common doses and brand/generic name of aprepitant/fosaprepitant.

A
28
Q

Identify the common doses and brand/generic name of prochlorperazine.

A
29
Q

Identify the common doses and brand/generic name of promethazine.

A
30
Q

Identify the common doses and brand/generic name of dexamethasone.

A
31
Q

Identify the common doses and brand/generic name of olanzapine.

A
32
Q

Summarize the evidence for agents used in treating and preventing CINV.

A
33
Q

Describe the principles of preventing CINV.

A
34
Q

Describe the principles of treating breakthrough CINV.

A
35
Q

LIST the goals of CINV treatment.

A
36
Q

Design a basic plan to prevent CINV.

A
37
Q

Summarize ASCO antiemetic guidelines by emetic risk category.

A
38
Q

Describe the rationale for different dexamethasone dosing with different NK-1 antagonists.

A
39
Q

Evaluate CINV clinical trial results.

A
40
Q

Use ASCO antiemetic guidelines to design regimens to prevent CINV.

A

IHOP (8 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions